Law360, New York (July 26, 2012, 6:13 PM ET) -- Human Genome Sciences Inc. on Thursday beat back two shareholder challenges to its $3 billion takeover by GlaxoSmithKline PLC, securing rejections of motions seeking to delay the close of the tender offer, which expires Friday.
In a Delaware federal case, a judge rejected arguments that shareholders needed more time to digest GSK's recently sweetened offer for Human Genome and to understand why the Maryland-based biotech firm had reversed course after three months of playing hard to get. The two companies agreed on a $14.25-per-share offer July...
GSK's $3B Takeover Of Human Genome Survives 2 Challenges
To view the full article, take a free trial now.
